Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to -$6.1 million.

  • Fortress Biotech's Cash from Operations rose 6953.99% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.1 million, marking a year-over-year increase of 3529.58%. This contributed to the annual value of -$80.2 million for FY2024, which is 3746.07% up from last year.
  • Per Fortress Biotech's latest filing, its Cash from Operations stood at -$6.1 million for Q3 2025, which was up 6953.99% from -$27.6 million recorded in Q2 2025.
  • Fortress Biotech's Cash from Operations' 5-year high stood at -$6.1 million during Q3 2025, with a 5-year trough of -$47.8 million in Q4 2022.
  • Its 5-year average for Cash from Operations is -$29.3 million, with a median of -$27.6 million in 2025.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 11606.42% in 2022, then soared by 6953.99% in 2025.
  • Over the past 5 years, Fortress Biotech's Cash from Operations (Quarter) stood at -$38.7 million in 2021, then decreased by 23.64% to -$47.8 million in 2022, then rose by 26.98% to -$34.9 million in 2023, then soared by 63.05% to -$12.9 million in 2024, then surged by 52.66% to -$6.1 million in 2025.
  • Its Cash from Operations stands at -$6.1 million for Q3 2025, versus -$27.6 million for Q2 2025 and -$19.6 million for Q1 2025.